

## Chapter 38

### REFERENCES

1. Campagna JA, Miller KW, Forman SA. Mechanisms of actions of inhaled anesthetics. *N Engl J Med.* 2003;348:2110-2124.
2. Keys, TE. *The History of Surgical Anesthesia*, 2nd ed. Dover Publications. New York, NY; 1963; 193.
3. Artusio JF Jr. Rationale and history of the development of halothane. *Clin Anesth.* 1968;1:1-10.
4. Weiskopf RB, Sampson D, More MA. The desflurane (Tec 6) vaporizer: design, design considerations and performance evaluation. *Br J Anaesth.* 1994;72:474-479.
5. Munson ES, Eger EI 2nd. The effects of hyperthermia and hypothermia on the rate of induction of anesthesia: calculations using a mathematical model. *Anesthesiology.* 1970;33:515-519.
6. Munson ES, Eger EI 2nd, Tham MK, Embro WJ. Increase in anesthetic uptake, excretion, and blood solubility in man after eating. *Anesth Analg.* 1978;57:224-231.
7. Levitt DG. PKQuest: volatile solutes: application to enflurane, nitrous oxide, halothane, methoxyflurane and toluene pharmacokinetics. *BMC Anesthesiol.* 2002;2:5.
8. Eger EI. Uptake of inhaled anesthetics: the alveolar to inspired anesthetic difference. In: Eger EI, ed. *Anesthetic Uptake and Action*. Baltimore, MD: Williams & Wilkins; 1974:77-96.
9. Baum JA. *Low Flow Anaesthesia: The Theory and Practice of Low Flow, Minimal Flow and Closed System Anaesthesia*. 2nd ed. Boston, MA: Butterworth-Heinemann; 2001.
10. Stoelting RK, Eger EI 2nd. An additional explanation for the second gas effect: a concentrating effect. *Anesthesiology.* 1969;30:273-277.
11. Taheri S, Eger EI 2nd. A demonstration of the concentration and second gas effects in humans anesthetized with nitrous oxide and desflurane. *Anesth Analg.* 1999;89:774-780.
12. Losasso TJ, Black S, Muzzi DA, et al. Detection and hemodynamic consequences of venous air embolism. Does nitrous oxide make a difference? *Anesthesiology.* 1992;77:148-152.
13. Losasso TJ, Muzzi DA, Dietz NM, Cucchiara RF. Fifty percent nitrous oxide does not increase the risk of venous air embolism in neurosurgical patients operated upon in the sitting position. *Anesthesiology.* 1992;77:21-30.
14. Hart RH, Vote BJ, Borthwick JH, et al. Loss of vision caused by expansion of intraocular perfluoropropane (C(3)F(8)) gas during nitrous oxide anesthesia. *Am J Ophthalmol.* 2002;134:761-763.
15. Seaberg RR, Freeman WR, Goldbaum MH, Manecke GR Jr. Permanent postoperative vision loss associated with expansion of intraocular gas in the presence of a nitrous oxide-containing anesthetic. *Anesthesiology.* 2002;97:1309-1310.
16. Grocott HP, Sato Y, Homi HM, Smith BE. The influence of xenon, nitrous oxide and nitrogen on gas bubble expansion during cardiopulmonary bypass. *Eur J Anaesthesiol.* 2005;22:353-358.
17. Lockwood G. Theoretical context-sensitive elimination times for inhalation anaesthetics. *Br J Anaesth.* 2010;104:648-655.
18. Urban BW, Bleckwenn M. Concepts and correlations relevant to general anaesthesia. *Br J Anaesth.* 2002;89:3-16.
19. Woodbridge PD. Changing concepts concerning depth of anesthesia. *Anesthesiology.* 1957;18:536-550.
20. Daniel M, Weiskopf RB, Noorani M, Eger EI 2nd. Fentanyl augments the blockade of the sympathetic response to incision (MAC-BAR) produced by desflurane and isoflurane: desflurane and isoflurane MAC-BAR without and with fentanyl. *Anesthesiology.* 1998;88:43-49.
21. Snow J. On the inhalation of the vapour of ether in surgical operations. London, UK: John Churchill; 1847.
22. Guedel A. *Inhalation Anaesthesia: A Fundamental Guide*. New York, NY: Macmillan; 1937.
23. Eger EI, Brandstater B. Minimal alveolar anesthetic concentration: a standard of anesthetic potency. *Anesthesiology.* 1965;26:756-763.
24. Eger EI 2nd. A brief history of the origin of minimum alveolar concentration (MAC). *Anesthesiology.* 2002;96:238-239.
25. Zbinden AM, Maggiorini M, Petersen-Felix S, et al. Anesthetic depth defined using multiple noxious stimuli during isoflurane/oxygen anesthesia. I. Motor reactions. *Anesthesiology.* 1994;80:253-260.
26. Eger EI 2nd. Age, minimum alveolar anesthetic concentration, and minimum alveolar anesthetic concentration-awake. *Anesth Analg.* 2001;93:947-953.
27. Nickalls RW, Mapleson WW. Age-related iso-MAC charts for isoflurane, sevoflurane and desflurane in man. *Br J Anaesth.* 2003;91:170-174.
28. Wadhwa A, Durrani J, Sengupta P, et al. Women have the same desflurane minimum alveolar concentration as men: a prospective study. *Anesthesiology.* 2003;99:1062-1065.
29. Gin T, Chan MT. Decreased minimum alveolar concentration of isoflurane in pregnant humans. *Anesthesiology.* 1994;81:829-832.
30. Stekiel TA, S JC, Bosnjak ZJ, et al. Reversal of minimum alveolar concentrations of volatile anesthetics by chromosomal substitution. *Anesthesiology.* 2004;101:796-798.

31. Liem EB, Lin CM, Suleman MI, et al. Anesthetic requirement is increased in redheads. *Anesthesiology*. 2004;101:279-283.
32. Xing Y, Sonner JM, Eger EI 2nd, et al. Mice with a melanocortin 1 receptor mutation have a slightly greater minimum alveolar concentration than control mice. *Anesthesiology*. 2004;101:544-546.
33. Eger EI 2nd, Xing Y, Laster M, et al. Halothane and isoflurane have additive minimum alveolar concentration (MAC) effects in rats. *Anesth Analg*. 2003;96:1350-1353, table of contents.
34. Firestone LL, Korpi ER, Niemi L, et al. Halothane and desflurane requirements in alcohol-tolerant and -nontolerant rats. *Br J Anaesth*. 2000;85:757-762.
35. Rampil IJ. Anesthetic potency is not altered after hypothermic spinal cord transection in rats. *Anesthesiology*. 1994;80:606-610.
36. Antognini JF, Schwartz K. Exaggerated anesthetic requirements in the preferentially anesthetized brain [comment]. *Anesthesiology*. 1993;79:1244-1249.
37. Zhou HH, Jin TT, Qin B, Turndorf H. Suppression of spinal cord motoneuron excitability correlates with surgical immobility during isoflurane anesthesia. *Anesthesiology*. 1998;88:955-961.
38. Zhou HH, Mehta M, Leis AA. Spinal cord motoneuron excitability during isoflurane and nitrous oxide anesthesia. *Anesthesiology*. 1997;86:302-307.
39. Rehberg B, Bouillon T, Gruenewald M, et al. Comparison of the concentration-dependent effect of sevoflurane on the spinal H-reflex and the EEG in humans. *Acta Anaesthesiol Scand*. 2004;48:569-576.
40. Dwyer R, Bennett HL, Eger EI 2nd, Heilbron D. Effects of isoflurane and nitrous oxide in subanesthetic concentrations on memory and responsiveness in volunteers. *Anesthesiology*. 1992;77:888-898.
41. Ben-David B, Vaida S, Gaitini L. The influence of high spinal anesthesia on sensitivity to midazolam sedation. *Anesth Analg*. 1995;81:525-528.
42. Tverskoy M, Shifrin V, Finger J, et al. Effect of epidural bupivacaine block on midazolam hypnotic requirements. *Reg Anesth*. 1996;21:209-213.
43. Hodgson PS, Liu SS. Epidural lidocaine decreases sevoflurane requirement for adequate depth of anesthesia as measured by the Bispectral Index monitor. *Anesthesiology*. 2001;94:799-803.
44. Hodgson PS, Liu SS, Gras TW. Does epidural anesthesia have general anesthetic effects? A prospective, randomized, double-blind, placebo-controlled trial. *Anesthesiology*. 1999;91:1687-1692.
45. Katoh T, Ikeda K. The effects of fentanyl on sevoflurane requirements for loss of consciousness and skin incision. *Anesthesiology*. 1998;88:18-24.
46. John ER, Prichep LS. The anesthetic cascade: a theory of how anesthesia suppresses consciousness. *Anesthesiology*. 2005;102:447-471.
47. Shields DC, Leiphart JW, McArthur DL, et al. Cortical synchrony changes detected by scalp electrode electroencephalograph as traumatic brain injury patients emerge from coma. *Surg Neurol*. 2007;67:354-359.
48. Mashour GA. Consciousness unbound: toward a paradigm of general anesthesia. *Anesthesiology*. 2004;100:428-433.
49. Peltier SJ, Keressens C, Hamann SB, et al. Functional connectivity changes with concentration of sevoflurane anesthesia. *Neuroreport*. 2005;16:285-258.
50. Alkire MT, Haier RJ, Fallon JH. Toward a unified theory of narcosis: brain imaging evidence for a thalamocortical switch as the neurophysiologic basis of anesthetic-induced unconsciousness. *Conscious Cogn*. 2000;9:370-386.
51. Keressens C, Klein J, Bonke B. Awareness: monitoring versus remembering what happened. *Anesthesiology*. 2003;99:570-575.
52. Alkire MT, Nathan SV. Does the amygdala mediate anesthetic-induced amnesia? Basolateral amygdala lesions block sevoflurane-induced amnesia. *Anesthesiology*. 2005;102:754-760.
53. Uchida S, Nakayama H, Maehara T, et al. Suppression of gamma activity in the human medial temporal lobe by sevoflurane anesthesia. *Neuroreport*. 2000;11:39-42.
54. Simon W, Hapfelmeier G, Kochs E, et al. Isoflurane blocks synaptic plasticity in the mouse hippocampus. *Anesthesiology*. 2001;94:1058-1065.
55. Roizen MF, Horrigan RW, Frazer BM. Anesthetic doses blocking adrenergic (stress) and cardiovascular responses to incision—MAC BAR. *Anesthesiology*. 1981;54:390-398.
56. Eckenhoff RG, Johansson JS, Wei H, et al. Inhaled anesthetic enhancement of amyloid-beta oligomerization and cytotoxicity. *Anesthesiology*. 2004;101:703-709.
57. Xie Z, Culley DJ, Dong Y, et al. The common inhalation anesthetic isoflurane induces caspase activation and increases amyloid beta-protein level in vivo. *Ann Neurol*. 2008;64:618-627.
58. Zhen Y, Dong Y, Wu X, et al. Nitrous oxide plus isoflurane induces apoptosis and increases beta-amyloid protein levels. *Anesthesiology*. 2009;111:741-752.
59. Monk TG, Saini V, Weldon BC, Sigl JC. Anesthetic management and one-year mortality after noncardiac surgery. *Anesth Analg*. 2005;100:4-10.
60. Song D, Joshi GP, White PF. Titration of volatile anesthetics using bispectral index facilitates recovery after ambulatory anesthesia. *Anesthesiology*. 1997;87:842-848.
61. White PF, Ma H, Tang J, et al. Does the use of electroencephalographic bispectral index or auditory evoked potential index monitoring facilitate recovery after desflurane anesthesia in the ambulatory setting? *Anesthesiology*. 2004;100:811-817.
62. Rampil IJ. A primer for EEG signal processing in anesthesia. *Anesthesiology*. 1998;89:980-1002.
63. Rosow C, Manberg PJ. Bispectral index monitoring. *Anesthesiol Clin North America*. 2001;19:947-966, xi.
64. Dressler O, Schneider G, Stockmanns G, Kochs EF. Awareness and the EEG power spectrum: analysis of frequencies. *Br J Anaesth*. 2004;93:806-809.
65. Vakkuri A, Yli-Hankala A, Talja P, et al. Time-frequency balanced spectral entropy as a measure of anesthetic drug effect in central nervous system during sevoflurane, propofol, and thiopental anesthesia. *Acta Anaesthesiol Scand*. 2004;48:145-153.
66. Ellerkmann RK, Liermann VM, Alves TM, et al. Spectral entropy and bispectral index as measures of the electroencephalographic effects of sevoflurane. *Anesthesiology*. 2004;101:1275-1282.
67. Scheller B, Schneider G, Daunderer M, et al. High-frequency components of auditory evoked potentials are detected in responsive but not in unconscious patients. *Anesthesiology*. 2005;103:944-950.
68. Ferrarelli F, Massimini M, Sarasso S, et al. Breakdown in cortical effective connectivity during midazolam-induced loss of consciousness. *Proc Natl Acad Sci U S A*. 2010;107:2681-2686.

69. Joint Council on Accreditation of Hospital Organizations (JCAHO). Preventing, and managing the impact of, anesthesia awareness. *Sentinel Event Alert*. 2004;6(32):1-3.
70. Sandin RH, Enlund G, Samuelsson P, Lennmarken C. Awareness during anaesthesia: a prospective case study. *Lancet*. 2000;355:707-711.
71. Sebel PS, Bowdle TA, Ghoneim MM, et al. The incidence of awareness during anesthesia: a multicenter United States study. *Anesth Analg*. 2004;99:833-839; table of contents.
72. Brice DD, Hetherington RR, Utting JE. A simple study of awareness and dreaming during anaesthesia. *Br J Anaesth*. 1970;42:535-542.
73. Osterman JE, van der Kolk BA. Awareness during anesthesia and posttraumatic stress disorder. *Gen Hosp Psychiatry*. 1998;20:274-281.
74. Osterman JE, Hopper J, Heran WJ, et al. Awareness under anesthesia and the development of posttraumatic stress disorder. *Gen Hosp Psychiatry*. 2001;23:198-204.
75. Ghoneim MM. Awareness during anesthesia. *Anesthesiology*. 2000;92:597-602.
76. Sandin R. Relax, be aware, and know what you are doing. *Acta Anaesthesiol Scand*. 2002;46:343-344.
77. Lennmarken C, Bildfors K, Enlund G, et al. Victims of awareness. *Acta Anaesthesiol Scand*. 2002;46:229-231.
78. Phillips AA, McLean RF, Devitt JH, Harrington EM. Recall of intraoperative events after general anaesthesia and cardiopulmonary bypass. *Can J Anaesth*. 1993;40:922-926.
79. Bogetz MS, Katz JA. Recall of surgery for major trauma. *Anesthesiology*. 1984;61:6-9.
80. Lyons G, Macdonald R. Awareness during caesarean section. *Anaesthesia* 1991;46:62-64.
81. Bergman IJ, Kluger MT, Short TG. Awareness during general anaesthesia: a review of 81 cases from the Anaesthetic Incident Monitoring Study. *Anaesthesia*. 2002;57:549-556.
82. Myles PS, Leslie K, McNeil J, et al. Bispectral index monitoring to prevent awareness during anaesthesia: the B-Aware randomised controlled trial. *Lancet*. 2004;363:1757-1763.
83. Dahaba AA. Different conditions that could result in the bispectral index indicating an incorrect hypnotic state. *Anesth Analg*. 2005;101:765-773.
84. Messner M, Beese U, Romstock J, et al. The bispectral index declines during neuromuscular block in fully awake persons. *Anesth Analg*. 2003;97:488-491, table of contents.
85. Liu N, Chazot T, Huybrechts I, et al. The influence of a muscle relaxant bolus on bispectral and Datex-Ohmeda entropy values during propofol-remifentanyl induced loss of consciousness. *Anesth Analg*. 2005;101:1713-1718.
86. Hirota K, Kubota T, Ishihara H, Matsuki A. The effects of nitrous oxide and ketamine on the bispectral index and 95% spectral edge frequency during propofol-fentanyl anaesthesia. *Eur J Anaesthesiol*. 1999;16:779-783.
87. Avidan MS, Zhang L, Burnside BA, et al. Anesthesia awareness and the bispectral index. *N Engl J Med*. 2008;358:1097-1108.
88. Sloan TB. Anesthetics and the brain. *Anesthesiol Clin North America*. 2002;20:265-292.
89. Matta BF, Heath KJ, Tipping K, Summors AC. Direct cerebral vasodilatory effects of sevoflurane and isoflurane. *Anesthesiology*. 1999;91:677-680.
90. Bedford NM, Hardman JG, Nathanson MH. Cerebral hemodynamic response to the introduction of desflurane: a comparison with sevoflurane. *Anesth Analg*. 2000;91:152-155.
91. Iida H, Ohata H, Iida M, et al. Isoflurane and sevoflurane induce vasodilation of cerebral vessels via ATP-sensitive K<sup>+</sup> channel activation. *Anesthesiology*. 1998;89:954-960.
92. Staunton M, Drexler C, Schmid PG 3rd, et al. Neuronal nitric oxide synthase mediates halothane-induced cerebral microvascular dilation. *Anesthesiology*. 2000;92:125-132.
93. Preckel B, Bolten J. Pharmacology of modern volatile anaesthetics. *Best Pract Res Clin Anaesthesiol*. 2005;19:331-348.
94. Wollman H, Alexander SC, Cohen PJ, et al. Cerebral Circulation of man during halothane anesthesia: effects of hypocarbia and of D-tubocurarine. *Anesthesiology*. 1964;25:180-184.
95. Lenz C, Rebel A, van Ackern K, et al. Local cerebral blood flow, local cerebral glucose utilization, and flow-metabolism coupling during sevoflurane versus isoflurane anesthesia in rats. *Anesthesiology*. 1998;89:1480-1488.
96. Oshima T, Karasawa F, Okazaki Y, et al. Effects of sevoflurane on cerebral blood flow and cerebral metabolic rate of oxygen in human beings: a comparison with isoflurane. *Eur J Anaesthesiol*. 2003;20:543-547.
97. Mielck F, Stephan H, Buhre W, et al. Effects of 1 MAC desflurane on cerebral metabolism, blood flow and carbon dioxide reactivity in humans. *Br J Anaesth*. 1998;81:155-160.
98. Mielck F, Stephan H, Weyland A, Sonntag H. Effects of one minimum alveolar anesthetic concentration sevoflurane on cerebral metabolism, blood flow, and CO<sub>2</sub> reactivity in cardiac patients. *Anesth Analg*. 1999;89:364-369.
99. Fraga M, Rama-Maceiras P, Rodino S, et al. The effects of isoflurane and desflurane on intracranial pressure, cerebral perfusion pressure, and cerebral arteriovenous oxygen content difference in normocapnic patients with supratentorial brain tumors. *Anesthesiology*. 2003;98:1085-1090.
100. Sponheim S, Skraastad O, Helseth E, et al. Effects of 0.5 and 1.0 MAC isoflurane, sevoflurane and desflurane on intracranial and cerebral perfusion pressures in children. *Acta Anaesthesiol Scand*. 2003;47:932-938.
101. Pelligrino DA, Miletich DJ, Hoffman WE, Albrecht RF. Nitrous oxide markedly increases cerebral cortical metabolic rate and blood flow in the goat. *Anesthesiology*. 1984;60:405-412.
102. Henriksen HT, Jorgensen PB. The effect of nitrous oxide on intracranial pressure in patients with intracranial disorders. *Br J Anaesth*. 1973;45:486-492.
103. Nakanishi O, Ishikawa T, Imamura Y, Hirakawa T. Inhibition of cerebral metabolic and circulatory responses to nitrous oxide by 6-hydroxydopamine in dogs. *Can J Anaesth*. 1997;44:1008-1013.
104. Kaieda R, Todd MM, Warner DS. The effects of anesthetics and PaCO<sub>2</sub> on the cerebrovascular, metabolic, and electroencephalographic responses to nitrous oxide in the rabbit. *Anesth Analg*. 1989;68:135-143.
105. Baughman VL, Hoffman WE, Miletich DJ, Albrecht RF. Cerebrovascular and cerebral metabolic effects of N<sub>2</sub>O in unrestrained rats. *Anesthesiology*. 1990;73:269-272.
106. Yli-Hankala A, Lindgren L, Porkkala T, Jantti V. Nitrous oxide-mediated activation of the EEG during isoflurane anaesthesia in patients. *Br J Anaesth*. 1993;70:54-57.
107. Anderson RE, Jakobsson JG. Entropy of EEG during anaesthetic induction: a comparative study with propofol or nitrous oxide as sole agent. *Br J Anaesth*. 2004;92:167-170.
108. Barr G, Jakobsson JG, Owall A, Anderson RE. Nitrous oxide does not alter bispectral index: study with nitrous oxide as

- sole agent and as an adjunct to i.v. anaesthesia. *Br J Anaesth.* 1999;82:827-830.
109. Neigh JL, Garman JK, Harp JR. The electroencephalographic pattern during anesthesia with ethrane: effects of depth of anesthesia, PaCO<sub>2</sub>, and nitrous oxide. *Anesthesiology.* 1971;35:482-487.
  110. Iijima T, Nakamura Z, Iwao Y, et al. The epileptogenic properties of the volatile anesthetics sevoflurane and isoflurane in patients with epilepsy. *Anesth Analg.* 2000;91:989-995.
  111. Hilty CA, Drummond JC. Seizure-like activity on emergence from sevoflurane anesthesia. *Anesthesiology.* 2000;93:1357-1359.
  112. Lowe D, Hettrick DA, Pagel PS, Warltier DC. Influence of volatile anesthetics on left ventricular afterload in vivo. Differences between desflurane and sevoflurane. *Anesthesiology.* 1996;85:112-120.
  113. Pac-Soo CK, Ma D, Wang C, et al. Specific actions of halothane, isoflurane, and desflurane on sympathetic activity and A delta and C somatosympathetic reflexes recorded in renal nerves in dogs. *Anesthesiology.* 1999;91:470-478.
  114. Ebert TJ, Kampine JP. Nitrous oxide augments sympathetic outflow: direct evidence from human peroneal nerve recordings. *Anesth Analg.* 1989;69:444-449.
  115. Smith NT, Eger EI 2nd, Stoelting RK, et al. The cardiovascular and sympathomimetic responses to the addition of nitrous oxide to halothane in man. *Anesthesiology.* 1970;32:410-421.
  116. Picker O, Scheeren TW, Arndt JO. Inhalation anaesthetics increase heart rate by decreasing cardiac vagal activity in dogs. *Br J Anaesth.* 2001;87:748-754.
  117. Weiskopf RB, Moore MA, Eger EI 2nd, et al. Rapid increase in desflurane concentration is associated with greater transient cardiovascular stimulation than with rapid increase in isoflurane concentration in humans. *Anesthesiology.* 1994;80:1035-1045.
  118. Ebert TJ, Muzi M, Lopatka CW. Neurocirculatory responses to sevoflurane in humans. A comparison to desflurane. *Anesthesiology.* 1995;83:88-95.
  119. Ebert TJ, Kotrly KJ, Vucins EJ, et al. Halothane anesthesia attenuates cardiopulmonary baroreflex control of peripheral resistance in humans. *Anesthesiology.* 1985;63:668-674.
  120. Kawamura R, Stanley TH, English JB, et al. Cardiovascular responses to nitrous oxide exposure for two hours in man. *Anesth Analg.* 1980;59:93-99.
  121. Hannon JD, Cody MJ, Sun DX, Housmans PR. Effects of isoflurane and sevoflurane on intracellular calcium and contractility in pressure-overload hypertrophy. *Anesthesiology.* 2004;101:675-686.
  122. Goldberg AH, Ullrich WC. Effects of halothane on isometric contractions of isolated heart muscle. *Anesthesiology.* 1967;28:838-845.
  123. Eger EI 2nd, Smith NT, Stoelting RK, et al. Cardiovascular effects of halothane in man. *Anesthesiology.* 1970;32:396-409.
  124. Gare M, Schwabe DA, Hettrick DA, et al. Desflurane, sevoflurane, and isoflurane affect left atrial active and passive mechanical properties and impair left atrial-left ventricular coupling in vivo: analysis using pressure-volume relations. *Anesthesiology.* 2001;95:689-698.
  125. Bartunek AE, Claes VA, Housmans PR. Effects of volatile anesthetics on stiffness of mammalian ventricular muscle. *J Appl Physiol.* 2001;91:1563-1573.
  126. Price HL. Myocardial depression by nitrous oxide and its reversal by Ca<sup>++</sup>. *Anesthesiology.* 1976;44:211-215.
  127. Carton EG, Wanek LA, Housmans PR. Effects of nitrous oxide on contractility, relaxation and the intracellular calcium transient of isolated mammalian ventricular myocardium. *J Pharmacol Exp Ther.* 1991;257:843-849.
  128. Huneke R, Fassl J, Rossaint R, Luckhoff A. Effects of volatile anesthetics on cardiac ion channels. *Acta Anaesthesiol Scand.* 2004;48:547-561.
  129. Sumikawa K, Ishizaka N, Suzaki M. Arrhythmogenic plasma levels of epinephrine during halothane, enflurane, and pentobarbital anesthesia in the dog. *Anesthesiology.* 1983;58:322-325.
  130. Navarro R, Weiskopf RB, Moore MA, et al. Humans anesthetized with sevoflurane or isoflurane have similar arrhythmic response to epinephrine. *Anesthesiology.* 1994;80:545-549.
  131. Moore MA, Weiskopf RB, Eger EI 2nd, et al. Arrhythmogenic doses of epinephrine are similar during desflurane or isoflurane anesthesia in humans. *Anesthesiology.* 1993;79:943-947.
  132. Guler N, Kati I, Demirel CB, et al. The effects of volatile anesthetics on the Q-Tc interval. *J Cardiothorac Vasc Anesth.* 2001;15:188-191.
  133. Yildirim H, Adanir T, Atay A, et al. The effects of sevoflurane, isoflurane and desflurane on QT interval of the ECG. *Eur J Anaesthesiol.* 2004;21:566-570.
  134. Rodrigo MR, Moles TM, Lee PK. Comparison of the incidence and nature of cardiac arrhythmias occurring during isoflurane or halothane anaesthesia. Studies during dental surgery. *Br J Anaesth.* 1986;58:394-400.
  135. Cripps TP, Edmondson RS. Isoflurane for anaesthesia in the dental chair. a comparison of the incidence of cardiac dysrhythmias during anaesthesia with halothane and isoflurane. *Anaesthesia.* 1987;42:189-191.
  136. Blayney MR, Malins AF, Cooper GM. Cardiac arrhythmias in children during outpatient general anaesthesia for dentistry: a prospective randomised trial. *Lancet.* 1999;354:1864-1866.
  137. Roizen MF, Plummer GO, Lichtor JL. Nitrous oxide and dysrhythmias. *Anesthesiology.* 1987;66:427-431.
  138. Liu WS, Wong KC, Port JD, Andriano KP. Epinephrine-induced arrhythmias during halothane anesthesia with the addition of nitrous oxide, nitrogen, or helium in dogs. *Anesth Analg.* 1982;61:414-417.
  139. Wilton NC, Knight PR, Ullrich K, et al. Transmural redistribution of myocardial blood flow during isoflurane anesthesia and its effects on regional myocardial function in a canine model of fixed coronary stenosis. *Anesthesiology.* 1993;78:510-523.
  140. Agnew NM, Pennefather SH, Russell GN. Isoflurane and coronary heart disease. *Anaesthesia.* 2002;57:338-347.
  141. Warltier DC, Pagel PS. Cardiovascular and respiratory actions of desflurane: is desflurane different from isoflurane? *Anesth Analg.* 1992;75:S17-S29; discussion S31.
  142. Kersten JR, Brayer AP, Pagel PS, et al. Perfusion of ischemic myocardium during anesthesia with sevoflurane. *Anesthesiology.* 1994;81:995-1004.
  143. Fourcade HE, Stevens WC, Larson CP Jr., et al. The ventilatory effects of Forane, a new inhaled anesthetic. *Anesthesiology.* 1971;35:26-31.
  144. Doi M, Ikeda K. Respiratory effects of sevoflurane. *Anesth Analg.* 1987;66:241-244.
  145. Lockhart SH, Rampil IJ, Yasuda N, et al. Depression of ventilation by desflurane in humans. *Anesthesiology.* 1991;74:484-488.
  146. Hornbein TF, Martin WE, Bonica JJ, et al. Nitrous oxide effects on the circulatory and ventilatory responses to halothane. *Anesthesiology.* 1969;31:250-260.

147. Hedenstierna G. Gas exchange pathophysiology during anesthesia. In Breen P, ed. *Respiration in Anesthesia*. Philadelphia, PA: WB Saunders; 1998:113-128.
148. Hirshman CA, McCullough RE, Cohen PJ, Weil JV. Depression of hypoxic ventilatory response by halothane, enflurane and isoflurane in dogs. *Br J Anaesth*. 1977;49:957-963.
149. Knill RL, Gelb AW. Ventilatory responses to hypoxia and hypercapnia during halothane sedation and anesthesia in man. *Anesthesiology*. 1978;49:244-251.
150. Groeben H, Meier S, Tankersley CG, et al. Influence of volatile anaesthetics on hypercapnoeic ventilatory responses in mice with blunted respiratory drive. *Br J Anaesth*. 2004;92:697-703.
151. Yacoub O, Doell D, Kryger MH, Anthonisen NR. Depression of hypoxic ventilatory response by nitrous oxide. *Anesthesiology*. 1976;45:385-389.
152. Sheffer L, Steffenson JL, Birch AA. Nitrous-oxide-induced diffusion hypoxia in patients breathing spontaneously. *Anesthesiology*. 1972;37:436-439.
153. Einarsson S, Stenqvist O, Bengtsson A, et al. Nitrous oxide elimination and diffusion hypoxia during normo- and hypoventilation. *Br J Anaesth*. 1993;71:189-193.
154. Liu R, Ueda M, Okazaki N, Ishibe Y. Role of potassium channels in isoflurane- and sevoflurane-induced attenuation of hypoxic pulmonary vasoconstriction in isolated perfused rabbit lungs. *Anesthesiology*. 2001;95:939-946.
155. Lejeune P, Deloof T, Leeman M, et al. Multipoint pulmonary vascular pressure/flow relationships in hypoxic and in normoxic dogs: effects of nitrous oxide with and without cyclooxygenase inhibition. *Anesthesiology*. 1988;68:92-99.
156. Marshall C, Lindgren L, Marshall BE. Effects of halothane, enflurane, and isoflurane on hypoxic pulmonary vasoconstriction in rat lungs in vitro. *Anesthesiology*. 1984;60:304-308.
157. Ishibe Y, Gui X, Uno H, et al. Effect of sevoflurane on hypoxic pulmonary vasoconstriction in the perfused rabbit lung. *Anesthesiology*. 1993;79:1348-1353.
158. Loer SA, Scheeren TW, Tarnow J. Desflurane inhibits hypoxic pulmonary vasoconstriction in isolated rabbit lungs. *Anesthesiology*. 1995;83:552-556.
159. Benumof JL, Wahrenbrock EA. Local effects of anesthetics on regional hypoxic pulmonary vasoconstriction. *Anesthesiology*. 1975;43:525-532.
160. Mathers J, Benumof JL, Wahrenbrock EA. General anesthetics and regional hypoxic pulmonary vasoconstriction. *Anesthesiology*. 1977;46:111-114.
161. Kerbaul F, Bellezza M, Guidon C, et al. Effects of sevoflurane on hypoxic pulmonary vasoconstriction in anaesthetized piglets. *Br J Anaesth*. 2000;85:440-445.
162. Kerbaul F, Guidon C, Stephanazzi J, et al. Sub-MAC concentrations of desflurane do not inhibit hypoxic pulmonary vasoconstriction in anesthetized piglets. *Can J Anaesth*. 2001;48:760-767.
163. Lennon PF, Murray PA. Attenuated hypoxic pulmonary vasoconstriction during isoflurane anesthesia is abolished by cyclooxygenase inhibition in chronically instrumented dogs. *Anesthesiology*. 1996;84:404-414.
164. Dikmen Y, Eminoglu E, Salihoglu Z, Demiroglu S. Pulmonary mechanics during isoflurane, sevoflurane and desflurane anaesthesia. *Anaesthesia*. 2003;58:745-748.
165. Rooke GA, Choi JH, Bishop MJ. The effect of isoflurane, halothane, sevoflurane, and thiopental/nitrous oxide on respiratory system resistance after tracheal intubation. *Anesthesiology*. 1997;86:1294-1299.
166. Goff MJ, Arain SR, Ficke DJ, et al. Absence of bronchodilation during desflurane anesthesia: a comparison to sevoflurane and thiopental. *Anesthesiology*. 2000;93:404-408.
167. TerRiet MF, DeSouza GJ, Jacobs JS, et al. Which is most pungent: isoflurane, sevoflurane or desflurane? *Br J Anaesth*. 2000;85:305-307.
168. Frink EJ Jr, Morgan SE, Coetzee A, et al. The effects of sevoflurane, halothane, enflurane, and isoflurane on hepatic blood flow and oxygenation in chronically instrumented greyhound dogs. *Anesthesiology*. 1992;76:85-90.
169. Gatecel C, Losser MR, Payen D. The postoperative effects of halothane versus isoflurane on hepatic artery and portal vein blood flow in humans. *Anesth Analg*. 2003;96:740-745, table of contents.
170. Vollmar B, Conzen PF, Kerner T, et al. Blood flow and tissue oxygen pressures of liver and pancreas in rats: effects of volatile anesthetics and of hemorrhage. *Anesth Analg*. 1992;75:421-430.
171. Tiainen P, Lindgren L, Rosenberg PH. Changes in hepatocellular integrity during and after desflurane or isoflurane anaesthesia in patients undergoing breast surgery. *Br J Anaesth*. 1998;80:87-89.
172. Holt C, Csete M, Martin P. Hepatotoxicity of anesthetics and other central nervous system drugs. *Gastroenterol Clin North Am*. 1995;24:853-874.
173. Spracklin DK, Hankins DC, Fisher JM, et al. Cytochrome P450 2E1 is the principal catalyst of human oxidative halothane metabolism in vitro. *J Pharmacol Exp Ther*. 1997;281:400-411.
174. Eger E. *Isoflurane (Forane). A Compendium and Reference*. 2nd edition. Madison, WI: Anaquest; 1985
175. Bastron RD, Perkins RM, Pyne JL. Autoregulation of renal blood flow during halothane anesthesia. *Anesthesiology*. 1977;46:142-144.
176. Kenna JG, Jones RM. The organ toxicity of inhaled anesthetics. *Anesth Analg*. 1995;81(Suppl):S51-S66.
177. Philbin DM, Coggins CH. The effects of anesthesia on antidiuretic hormone. *Contemp Anesth Pract*. 1980;3:29-38.
178. Wulf H, Hauschild S, Proppe D, Ledowski T. [Augmentation of the neuromuscular blocking effect of mivacurium during inhalation anesthesia with desflurane, sevoflurane and isoflurane in comparison with total intravenous anesthesia]. *Anaesthesiol Reanim*. 1998;23:88-92.
179. Uesugi T, Mikawa K, Nishina K, et al. Effects of phosphodiesterase-III inhibitors on sevoflurane-induced impairment of rat diaphragmatic function. *Acta Anaesthesiol Scand*. 2005;49:819-826.
180. Nishina K, Mikawa K, Kodama S, et al. The effects of enflurane, isoflurane, and intravenous anesthetics on rat diaphragmatic function and fatigability. *Anesth Analg*. 2003;96:1674-1678, table of contents.
181. Priori SG, Napolitano C. Cardiac and skeletal muscle disorders caused by mutations in the intracellular Ca<sup>2+</sup> release channels. *J Clin Invest*. 2005;115:2033-2038.
182. Kinsella LJ, Green R. "Anesthesia paresthetica": nitrous oxide-induced cobalamin deficiency. *Neurology*. 1995;45:1608-1610.
183. Selzer RR, Rosenblatt DS, Laxova R, Hogan K. Adverse effect of nitrous oxide in a child with 5,10-methylenetetrahydrofolate reductase deficiency. *N Engl J Med*. 2003;349:45-50.

184. Geisser W, Schreiber M, Hofbauer H, et al. Sevoflurane versus isoflurane—anaesthesia for lower abdominal surgery. Effects on perioperative glucose metabolism. *Acta Anaesthesiol Scand*. 2003;47:174-179.
185. Marana E, Annetta MG, Meo F, et al. Sevoflurane improves the neuroendocrine stress response during laparoscopic pelvic surgery. *Can J Anaesth*. 2003;50:348-354.
186. Frohlich D, Rothe G, Schwall B, et al. Effects of volatile anaesthetics on human neutrophil oxidative response to the bacterial peptide FMLP. *Br J Anaesth*. 1997;78:718-723.
187. Loop T, Scheiermann P, Doviakue D, et al. Sevoflurane inhibits phorbol-myristate-acetate-induced activator protein-1 activation in human T lymphocytes in vitro: potential role of the p38-stress kinase pathway. *Anesthesiology*. 2004;101:710-721.
188. Loop T, Dovi-Akue D, Frick M, et al. Volatile anaesthetics induce caspase-dependent, mitochondria-mediated apoptosis in human T lymphocytes in vitro. *Anesthesiology*. 2005;102:1147-1157.
189. Giraud O, Molliex S, Rolland C, et al. Halogenated anaesthetics reduce interleukin-1beta-induced cytokine secretion by rat alveolar type II cells in primary culture. *Anesthesiology*. 2003;98:74-81.
190. Siebert JN, Posfay-Barbe KM, Habre W, Siegrist CA. Influence of anesthesia on immune responses and its effect on vaccination in children: review of evidence. *Paediatr Anaesth*. 2007;17:410-420.
191. Julier K, da Silva R, Garcia C, et al. Preconditioning by sevoflurane decreases biochemical markers for myocardial and renal dysfunction in coronary artery bypass graft surgery: a double-blinded, placebo-controlled, multicenter study. *Anesthesiology*. 2003;98:1315-1327.
192. Lee HT, Ota-Setlik A, Fu Y, et al. Differential protective effects of volatile anaesthetics against renal ischemia-reperfusion injury in vivo. *Anesthesiology*. 2004;101:1313-1324.
193. Kapinya KJ, Lowl D, Futterer C, et al. Tolerance against ischemic neuronal injury can be induced by volatile anaesthetics and is inducible NO synthase dependent. *Stroke*. 2002;33:1889-1898.
194. Xiong L, Zheng Y, Wu M, et al. Preconditioning with isoflurane produces dose-dependent neuroprotection via activation of adenosine triphosphate-regulated potassium channels after focal cerebral ischemia in rats. *Anesth Analg*. 2003;96:233-237, table of contents.
195. Szyfter K, Szulc R, Mikstacki A, et al. Genotoxicity of inhalation anaesthetics: DNA lesions generated by sevoflurane in vitro and in vivo. *J Appl Genet*. 2004;45:369-374.
196. Fujinaga M, Mazze RI, Baden JM, et al. Rat whole embryo culture: an in vitro model for testing nitrous oxide teratogenicity. *Anesthesiology*. 1988;69:401-404.
197. Burm AG. Occupational hazards of inhalational anaesthetics. *Best Pract Res Clin Anaesthesiol*. 2003;17:147-161.
198. Kuczkowski KM. Sevoflurane and seizures: déjà vu. *Acta Anaesthesiol Scand*. 2004;48:1216.
199. Fang ZX, Kandel L, Laster MJ, et al. Factors affecting production of compound A from the interaction of sevoflurane with Baralyme and soda lime. *Anesth Analg*. 1996;82:775-781.
200. Gonsowski CT, Laster MJ, Eger EI 2nd, et al. Toxicity of compound A in rats. Effect of a 3-hour administration. *Anesthesiology*. 1994;80:556-565.
201. Iyer RA, Anders MW. Cysteine conjugate beta-lyase-dependent biotransformation of the cysteine S-conjugates of the sevoflurane degradation product compound A in human, nonhuman primate, and rat kidney cytosol and mitochondria. *Anesthesiology*. 1996;85:1454-1461.
202. Sheffels P, Schroeder JL, Altuntas TG, et al. Role of cytochrome P4503A in cysteine S-conjugates sulfoxidation and the nephrotoxicity of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in rats. *Chem Res Toxicol*. 2004;17:1177-1189.
203. Eger EI 2nd, Koblin DD, Bowland T, et al. Nephrotoxicity of sevoflurane versus desflurane anesthesia in volunteers. *Anesth Analg*. 1997;84:160-168.
204. Conzen PF, Kharasch ED, Czerner SF, et al. Low-flow sevoflurane compared with low-flow isoflurane anesthesia in patients with stable renal insufficiency. *Anesthesiology*. 2002;97:578-584.
205. Wu J, Previte JP, Adler E, et al. Spontaneous ignition, explosion, and fire with sevoflurane and barium hydroxide lime. *Anesthesiology*. 2004;101:534-537.
206. Fatheree RS, Leighton BL. Acute respiratory distress syndrome after an exothermic Baralyme-sevoflurane reaction. *Anesthesiology*. 2004;101:531-533.
207. Berry PD, Sessler DI, Larson MD. Severe carbon monoxide poisoning during desflurane anesthesia. *Anesthesiology*. 1999;90:613-616.
208. Laster M, Roth P, Eger EI 2nd. Fires from the interaction of anaesthetics with desiccated absorbent. *Anesth Analg*. 2004;99:769-774, table of contents.
209. Wissing H, Kuhn I, Warnken U, Dudziak R. Carbon monoxide production from desflurane, enflurane, halothane, isoflurane, and sevoflurane with dry soda lime. *Anesthesiology*. 2001;95:1205-1212.
210. Keijzer C, Perez RS, De Lange JJ. Carbon monoxide production from five volatile anaesthetics in dry sodalime in a patient model: halothane and sevoflurane do produce carbon monoxide; temperature is a poor predictor of carbon monoxide production. *BMC Anesthesiol*. 2005;5:6.
211. Logan M, Farmer JG. Anaesthesia and the ozone layer. *Br J Anaesth*. 1989;63:645-647.
212. Westhorpe R, Blutstein H. Anaesthetic agents and the ozone layer. *Anaesth Intensive Care*. 1990;18:102-104.
213. Ravishankara AR, Daniel JS, Portmann RW. Nitrous oxide (N<sub>2</sub>O): the dominant ozone-depleting substance emitted in the 21st century. *Science*. 2009;326:123-125.
214. Ryan SM, Nielsen CJ. Global warming potential of inhaled anaesthetics: application to clinical use. *Anesth Analg*. 2010;111:92-98.
215. Ray DC, Drummond GB. Halothane hepatitis. *Br J Anaesth*. 1991;67:84-99.
216. Weitz J, Kienle P, Bohrer H, et al. Fatal hepatic necrosis after isoflurane anaesthesia. *Anaesthesia*. 1997;52:892-895.
217. Anders MW. Formation and toxicity of anaesthetic degradation products. *Annu Rev Pharmacol Toxicol*. 2005;45:147-176.
218. Kharasch ED, Hankins DC, Thummel KE. Human kidney methoxyflurane and sevoflurane metabolism. Intrarenal fluoride production as a possible mechanism of methoxyflurane nephrotoxicity. *Anesthesiology*. 1995;82:689-699.
219. Preckel B, Schlack W. Inert gases as the future inhalational anaesthetics? *Best Pract Res Clin Anaesthesiol*. 2005;19:365-379.
220. Lynch C 3rd, Baum J, Tenbrinck R. Xenon anesthesia. *Anesthesiology*. 2000;92:865-868.

221. Ma D, Hossain M, Chow A, et al. Xenon and hypothermia combine to provide neuroprotection from neonatal asphyxia. *Ann Neurol.* 2005;58:182-193.
222. Ma D, Yang H, Lynch J, et al. Xenon attenuates cardiopulmonary bypass-induced neurologic and neurocognitive dysfunction in the rat. *Anesthesiology.* 2003;98:690-698.
223. Coburn M, Baumert JH, Roertgen D, et al. Emergence and early cognitive function in the elderly after xenon or desflurane anaesthesia: a double-blinded randomized controlled trial. *Br J Anaesth.* 2007;98:756-762.
224. Hocker J, Stapelfeldt C, Leiendecker J, et al. Postoperative neurocognitive dysfunction in elderly patients after xenon versus propofol anesthesia for major noncardiac surgery: a double-blinded randomized controlled pilot study. *Anesthesiology.* 2009;110:1068-1076.
225. Kennedy RR, French RA, Spencer C. Predictive accuracy of a model of volatile anesthetic uptake. *Anesth Analg.* 2002;95:1616-1621, table of contents.
226. Mapleson WW. An electric analogue for uptake and exchange of inert gases and other agents. *J Appl Physiol.* 1963;18:197-204.